13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q4 2023 · Filed November 13, 2023 · Accession 0001104659-23-117291
Total Value
$180.0M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | PHVS | 3,743,450 | $78.1M | 43.39% |
| 2 | Cymabay Therapeutics, Inc. | 23257D103 | 1,787,094 | $26.6M | 14.80% |
| 3 | Aclaris Therapeutics, Inc. | ACRS | 2,808,034 | $19.2M | 10.68% |
| 4 | Kura Oncology, Inc. | KURA | 1,849,947 | $16.9M | 9.37% |
| 5 | Kinnate Biopharma Inc. | 49705R105 | 9,671,643 | $13.5M | 7.52% |
| 6 | Lyell Immunopharma, Inc. | LYEL | 8,784,813 | $12.9M | 7.17% |
| 7 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $12.7M | 7.06% |